Additionally, lapatinib can inhibit HER1, and trastuzumab induces apoptosis of cancer cells by blocking the HER2 signal pathway and the antibody-dependent cell-mediated cytotoxicity effect, which could lead to different anti-cancer effects and mechanisms of resistance. Here, ERBB2 is linked to cancer.